ArticleFrontiers in oncology2025

Cost-effectiveness analysis of the combination of low-dose nivolumab with triple metronomic chemotherapy for advanced head and neck squamous cell carcinoma in China.

Yingdan Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.